Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events than those receiving aspirin alone. Rivaroxaban alone did not result in fewer major cardiovascular events than aspirin alone.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 377; no. 14; pp. 1319 - 1330
Main Authors: Eikelboom, John W, Connolly, Stuart J, Bosch, Jackie, Dagenais, Gilles R, Hart, Robert G, Shestakovska, Olga, Diaz, Rafael, Alings, Marco, Lonn, Eva M, Anand, Sonia S, Widimsky, Petr, Hori, Masatsugu, Avezum, Alvaro, Piegas, Leopoldo S, Branch, Kelley R.H, Probstfield, Jeffrey, Bhatt, Deepak L, Zhu, Jun, Liang, Yan, Maggioni, Aldo P, Lopez-Jaramillo, Patricio, O’Donnell, Martin, Kakkar, Ajay K, Fox, Keith A.A, Parkhomenko, Alexander N, Ertl, Georg, Störk, Stefan, Keltai, Matyas, Ryden, Lars, Pogosova, Nana, Dans, Antonio L, Lanas, Fernando, Commerford, Patrick J, Torp-Pedersen, Christian, Guzik, Tomek J, Verhamme, Peter B, Vinereanu, Dragos, Kim, Jae-Hyung, Tonkin, Andrew M, Lewis, Basil S, Felix, Camilo, Yusoff, Khalid, Steg, P. Gabriel, Metsarinne, Kaj P, Cook Bruns, Nancy, Misselwitz, Frank, Chen, Edmond, Leong, Darryl, Yusuf, Salim
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 05.10.2017
Subjects:
Aged
Anticoagulants
Arteriosclerosis
Aspirin
Aspirin - adverse effects
Aspirin - therapeutic use
Atherosclerosis
Atherosclerosis - complications
Atherosclerosis - drug therapy
Bleeding
Cardiovascular disease
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - mortality
Cardiovascular Diseases - prevention & control
Cerebral infarction
Coronary vessels
Disease prevention
Double-Blind Method
Drug dosages
Drug therapy
Drug Therapy, Combination
Factor Xa Inhibitors - adverse effects
Factor Xa Inhibitors - therapeutic use
Female
Hemorrhage - chemically induced
Human health and pathology
Humans
Life Sciences
Male
Medical research
Middle Aged
Myocardial infarction
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
Rivaroxaban - adverse effects
Rivaroxaban - therapeutic use
Secondary Prevention - methods
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events than those receiving aspirin alone. Rivaroxaban alone did not result in fewer major cardiovascular events than aspirin alone.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1709118